Prospective phase 2 trials on high-dose chemotherapy supported by autologous stem cell transplantation
| Ref. . | No. of patients . | Median age, y (range) . | Treatment line . | Therapy, induction→intensification . | Conditioning regimen . | WBRT . | Outcome, % . | Neurotoxicity, % . | Median follow-up, mo . | TRM, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| 87 | 22 | 53 (27-64) | Salvage | araC + VP16 | Bu/TT/Cy | No | 3-y OS: 64 | 32 | 41 | 4 |
| 59 | 43 | 52 (23-65) | Salvage | araC + VP16 | Bu/TT/Cy | No | 2-y OS: 45 | 5 | 36 | 7 |
| 88 | 6 | 53 (30-66) | First-line | MBVP→IFO + araC | BEAM | Yes | 2-y OS: 40 | 33 | 41 | 0 |
| 89 | 25 | 52 (21-60) | First-line | MBVP→IFO + araC | BEAM | Yes | 4-y OS: 64 | 8 | 34 | 4 |
| 61 | 28 | 53 (25-71) | First-line | HD-MTX→araC | BEAM | No | 2-y OS: 55 | 0 | 28 | 4 |
| 90 | 23 | 55 (18-69) | First-line | HD-MTX→ | Bu/TT | Yes* | 2-y OS: 48 | 39 | 15 | 13 |
| 91 | 7 | 56 (41-64) | First-line† | HD-MTX→araC | Bu/TT/Cy | No | 3-y OS: 50 | 0 | 28 | 14 |
| 92 | 30 | 54 (27-64) | First-line | HD-MTX→araC + TT | BCNU/TT | Yes | 5-y OS: 69 | 17 | 63 | 3 |
| 78 | 13 | 54 (38-67) | First-line | HD-MTX→araC + TT | BCNU/TT | Yes* | 3-y OS: 77 | 0 | 23 | 0 |
| Ref. . | No. of patients . | Median age, y (range) . | Treatment line . | Therapy, induction→intensification . | Conditioning regimen . | WBRT . | Outcome, % . | Neurotoxicity, % . | Median follow-up, mo . | TRM, % . |
|---|---|---|---|---|---|---|---|---|---|---|
| 87 | 22 | 53 (27-64) | Salvage | araC + VP16 | Bu/TT/Cy | No | 3-y OS: 64 | 32 | 41 | 4 |
| 59 | 43 | 52 (23-65) | Salvage | araC + VP16 | Bu/TT/Cy | No | 2-y OS: 45 | 5 | 36 | 7 |
| 88 | 6 | 53 (30-66) | First-line | MBVP→IFO + araC | BEAM | Yes | 2-y OS: 40 | 33 | 41 | 0 |
| 89 | 25 | 52 (21-60) | First-line | MBVP→IFO + araC | BEAM | Yes | 4-y OS: 64 | 8 | 34 | 4 |
| 61 | 28 | 53 (25-71) | First-line | HD-MTX→araC | BEAM | No | 2-y OS: 55 | 0 | 28 | 4 |
| 90 | 23 | 55 (18-69) | First-line | HD-MTX→ | Bu/TT | Yes* | 2-y OS: 48 | 39 | 15 | 13 |
| 91 | 7 | 56 (41-64) | First-line† | HD-MTX→araC | Bu/TT/Cy | No | 3-y OS: 50 | 0 | 28 | 14 |
| 92 | 30 | 54 (27-64) | First-line | HD-MTX→araC + TT | BCNU/TT | Yes | 5-y OS: 69 | 17 | 63 | 3 |
| 78 | 13 | 54 (38-67) | First-line | HD-MTX→araC + TT | BCNU/TT | Yes* | 3-y OS: 77 | 0 | 23 | 0 |
araC indicates cytarabine; BCNU, carmustine; BEAM, carmustine, etoposide, cytarabine, and melphalan; Bu, busulfan; Cy, cyclophosphamide; IFO, ifosfamide; MBVP (regimen), methotrexate, carmustine, etoposide, and methylprednisolone; OS, overall survival; TRM, treatment-related mortality; TT, thiotepa; VP16, etoposide; and WBRT, whole-brain irradiation.
Only for patients not achieving a complete remission.
One patient received the treatment as salvage therapy.